XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.5.0.2

LICENSE AGREEMENTS (Details) |  |  | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Sep. 15, 2016 USD ($) item | Dec. 15, 2014 USD ($) item | Sep. 30, 2016 USD ($) | Sep. 30, 2015 USD ($) | Sep. 30, 2016 USD ($) | Sep. 30, 2015 USD ($) | Dec. 31, 2015 USD ($)
LICENSE AGREEMENTS |  |  |  |  |  |  |
License fee revenue |  |  | $ 5,108,000 | $ 363,000 | $ 6,068,000 | $ 1,151,000 |
Collaboration revenue |  |  |  | $ 35,000,000 |  | $ 35,000,000 |
Accrued collaboration charges |  |  | 3,398,000 |  | $ 3,398,000 |  | $ 2,328,000
Janssen Pharmaceuticals | License agreements |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |
Upfront Payment | $ 5,000,000 |  |  |  |  |  |
License fee revenue |  |  | $ 5,000,000 |  |  |  |
Least number of products under License Agreement | item | 1 |  |  |  |  |  |
Percentage of costs to be paid by Geron | 50.00% |  |  |  |  |  |
Percentage of costs to be paid by Janssen Pharmaceuticals | 50.00% |  |  |  |  |  |
Aggregate maximum total payments for development and regulatory milestones under license agreement | $ 75,000,000 |  |  |  |  |  |
Tiered royalties percentage range | low single digit |  |  |  |  |  |
Initial Period | Janssen Biotech | License agreements |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |
Upfront payment received |  | $ 35,000,000 |  |  |  |  |
Number of agreed upon studies | item |  | 2 |  |  |  |  |
Percentage of costs to be paid by Geron |  | 50.00% |  |  |  |  |
Percentage of costs to be paid by Janssen |  | 50.00% |  |  |  |  |
Notification period |  | 24 months |  |  |  |  |
U.S. Opt-In Rights exercised | Janssen Biotech | License agreements |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |
Percentage of costs to be paid by Geron |  | 20.00% |  |  |  |  |
Percentage of costs to be paid by Janssen |  | 80.00% |  |  |  |  |
Continuation Election milestone payment |  | $ 65,000,000 |  |  |  |  |
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement |  | 470,000,000 |  |  |  |  |
Aggregate maximum total of payments for sales milestones under collaboration agreement |  | $ 350,000,000 |  |  |  |  |
Tiered royalties percentage, low end of the range |  | mid-teens |  |  |  |  |
Tiered royalties percentage, high end of the range |  | low twenties |  |  |  |  |
U.S. selling effort percentage |  | 20.00% |  |  |  |  |
U.S. Opt-In Rights not exercised | Janssen Biotech | License agreements |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |
Continuation Election milestone payment |  | $ 65,000,000 |  |  |  |  |
Aggregate maximum total payments for development and regulatory milestones under collaboration agreement |  | 415,000,000 |  |  |  |  |
Aggregate maximum total of payments for sales milestones under collaboration agreement |  | $ 350,000,000 |  |  |  |  |
Tiered royalties percentage, low end of the range |  | double-digit |  |  |  |  |
Tiered royalties percentage, high end of the range |  | mid-teens |  |  |  |  |
Full U.S. Rights fee |  | $ 70,000,000 |  |  |  |  |
Collaborative Arrangement IP Exclusively Licensed | Janssen Biotech | License agreements |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |
Percentage of costs to be paid by Geron |  | 50.00% |  |  |  |  |
Percentage of costs to be paid by Janssen |  | 50.00% |  |  |  |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable to collaboration partner for which invoices have not yet been received under the respective collaboration agreement (due within one year or within the normal operating cycle if longer). + References No definition available. + Details
Name: | gern_CollaborativeArrangementAccruedCollaborationChargesCurrent
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of consideration that Geron will receive upon Janssen providing a positive Continuation Election notice. + References No definition available. + Details
Name: | gern_CollaborativeArrangementContinuationElectionMilestonePayment
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the aggregate maximum consideration that Geron could receive from attaining certain development and regulatory milestone events under the collaboration agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementDevelopmentAndRegulatoryMilestonesAggregateMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the consideration that Geron will receive from Janssen upon Geron's decision to opt-out of further development cost sharing after Janssen's positive Continuation Election notice. + References No definition available. + Details
Name: | gern_CollaborativeArrangementFullUSRightsFee
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of costs that Geron must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementGeronCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of costs that Janssen must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementJanssenCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the latest notification period from Janssen to Geron in the event of early termination or suspension of the Initial Phase 2 MF Study. + References No definition available. + Details
Name: | gern_CollaborativeArrangementNotificationPeriod
Namespace Prefix: | gern_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of agreed upon studies. + References No definition available. + Details
Name: | gern_CollaborativeArrangementNumberOfStudies
Namespace Prefix: | gern_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the aggregate maximum consideration that Geron could receive from attaining certain sales milestone events under the collaboration agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementSalesMilestonesAggregateMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of sales effort that Geron can provide in lieu of funding the same percentage of promotion costs upon regulatory approval and commercial launch of imetelstat in the U.S. + References No definition available. + Details
Name: | gern_CollaborativeArrangementSellingEffortPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the high end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat. + References No definition available. + Details
Name: | gern_CollaborativeArrangementTieredRoyaltiesPercentageHighEndOfRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the low end of the range of tiered royalty percentages to be applied to worldwide net sales of imetelstat. + References No definition available. + Details
Name: | gern_CollaborativeArrangementTieredRoyaltiesPercentageLowEndOfRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the least number of products required to be developed under the License Agreement. + References No definition available. + Details
Name: | gern_LeastNumberOfProductsUnderLicenseAgreement
Namespace Prefix: | gern_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum consideration that Geron could receive from attaining certain development and regulatory milestone events under the license agreement. + References No definition available. + Details
Name: | gern_LicenseAgreementDevelopmentAndRegulatoryMilestoneAggregateMaximum
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of costs Geron must pay during certain phases of the license agreement. + References No definition available. + Details
Name: | gern_LicenseAgreementGeronCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of costs that Janssen Pharma must pay during certain phases of the license agreement. + References No definition available. + Details
Name: | gern_LicenseAgreementJanssenPharmaCostSharingPercentage
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the range of tiered royalty percentages to be applied to worldwide net sales of licensed products under the License Agreement. + References No definition available. + Details
Name: | gern_LicenseAgreementTieredRoyaltiesPercentageRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References No definition available. + Details
Name: | gern_LicensesAndRoyaltyRevenue
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment received from Janssen upon effectiveness of Collaboration Agreement. + References No definition available. + Details
Name: | gern_UpfrontPaymentReceivedFromJanssenUnderCollaborationAgreement
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment under License Agreement. + References No definition available. + Details
Name: | gern_UpfrontPaymentUnderLicenseAgreement
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_ContractsRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=gern_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=gern_InitialPeriodMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=gern_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=gern_RightsExercisedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=gern_RightsNotExercisedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=gern_CollaborativeArrangementIPExclusivelyLicensedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |